Description
ADCC-Enhanced anti-IRTA-2 (8A1) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IRTA-2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IRTA-2
Full Name
Immune receptor Translocation Associated proteins
Background
The Immune receptor Translocation Associated (IRTA) genes/proteins consist of a five-member family of immunoglobulin-like cell surface receptors. The IRTAs were initially discovered by analysis of the breakpoints of a multiple myeloma cell line which contained a Iq21 chromosomal rearrangement. Each of the IRTA glycoproteins contains between 3 to 9 extracellular Ig-like domains. IRTAs are also characterized by having a cytoplasmic domain containing 3 to 5 tyrosine residues contained within particular motifs, suggesting the presence of immunotyrosine inhibitory motifs (ITIM) and immunotyrosine activation-like (ITAM-like) motifs.
Alternative Names
IRTA; Immune receptor Translocation Associated proteins; Fc receptor Homolog; FcRH
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with FCRL4 include Mulchandani-Bhoj-Conlin Syndrome and Lymphoma.
Function
May function as an inhibitor of the B-cell receptor signaling. May function in the B-cell-mediated immune response.
Post-translational modifications
1.Phosphorylated on cytoplasmic tyrosines upon activation 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn374
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
8A1
Description
The monoclonal antibody that specifically bind to IRTA-2 with high affinity are used for treating various B cell malignancies, including non-Hodgkin's lymphoma.
Antibody Indication
Cancer
